Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer

British Journal of Cancer

Volumn 103, Issue 6, 2010, Pages 787-795

  Okugawa, Y ^a   Miki, C ^a   Toiyama, Y ^a   Yasuda, H ^a   Yokoe, T ^a   Saigusa, S ^a   Hiro, J ^a   Tanaka, K ^a   Inoue, Y ^a   Kusunoki, M ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

colorectal cancer; interleukin 6; soluble interleukin 6 receptor; trans signalling

Indexed keywords

INTERLEUKIN 6 RECEPTOR; PRIMER DNA;

COLORECTAL TUMOR; DISEASE COURSE; FEMALE; HT 29 CELL LINE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY;

BASE SEQUENCE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA PRIMERS; FEMALE; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; RECEPTORS, INTERLEUKIN-6;

EID: 77956448658     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605827     Document Type: Article

References (39)

1. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Toshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501
2. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S, Neurath MF (2005) IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4: 217-220
3. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M, Greten FR (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102
4. Chung YC, Chang YF (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83: 222-226
5. Kovacs E (2001) Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother 55: 391-396
6. Egler RA, Burlingame SM, Nuchtern JG, Russell HV (2008) Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin Cancer Res 14: 7028-7034
7. Gaillard JP, Pugniere M, Tresca JP, Mani JV, Klein B, Brochier J (1999) Bio-availability of interleukin-6 in serum. Eur Cytokine Netw 10: 337-343
8. Galizia G, Ordituraing M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F (2002) Prognostic significance of circulating IL-10 and IL-6 levels in colon cancer patients undergoing surgery. Clin Immunol 102: 169-178
9. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103-113
10. Hatada T, Miki C (2000) Nutritional status and postoperative cytokine response in colorectal cancer patients. Cytokine 12: 1331-1336
11. Higaki S, Akazawa A, Nakamura H, Yanai H, Yoshida T, Okita K (1999) Metaplastic polyp of the colon develops in response to inflammation. J Gastroenterol Hepatol 14: 709-714
12. Hong DS, Angelo LS, Kurzrock R (2007) Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110: 1911-1928
13. Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, Matsumoto A, Yamamoto M, Yamamoto N (1994) Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 24: 1945-1948
14. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD (1997) The codependence of angiogenesis and chronic inflammation. Faseb J 11: 457-465
15. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000) Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangio-carcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60: 184-190
16. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. Faseb J 15: 43-58
17. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Auto-crine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85
18. Kinoshita T, Ito H, Miki C (1999) Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85: 2526-2531
19. Komatsu K, Andoh A, Ishiguro S, Suzuki N, Hunai H, Kobune-Fujiwara Y, Kameyama M, Miyoshi J, Akedo H, Nakamura H (2000) Increased expression of S100A6 (Calcyclin), a calcium-binding protein of the S100 family, in human colorectal adenocarcinomas. Clin Cancer Res 6: 172-177
20. Konishi N, Miki C, Yoshida T, Tanaka K, Toiyama Y, Kusunoki M (2005) Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma. Oncology 68: 138-145
21. Lauta VM (2003) A review of the cytokine network in multiplemyeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97: 2440-2452
22. Lee JD, Sievers TM, Skotzko M, Chandler CF, Morton DL, McBride WH, Economou JS (1992) Interleukin-6 production by human myeloma cell lines. Lymphokine Cytokine Res 11: 161-166
23. Meir EV, Sawamura Y, Diserens A, Hamou M, Tribolet N (1990) Human glioblastoma cells release interleukin-6 in vivo and in vitro. Cancer Res 50: 6683-6688
24. Miki C, Tanaka K, Toiyama Y, Inoue Y, Uchida K, Mohri Y, Kusunoki M (2009) Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 251: 389-390
25. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250: 607-610
26. Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, Mackiewicz A, Heinrich PC, Rose-John S (1993) The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 23: 473-480 (Pubitemid 23075080)
27. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T (1993) Soluble forms of the interleukin-6 signal-transducing component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82: 1120-1126
28. Ohsaki Y, Takahashi S, Scarcez T, Nishihara T, Williams R, Roodman GD (1992) Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cell tumors of bone. Endocrinology 131: 2229-2234
29. Oka M, Iizuka N, Yamamoto K, Gondo T, Abe T, Hazama S, Akitomi Y, Koshihara Y, Ohsugi Y, Ooba Y, Ishihara T, Suzuki T (1996) The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 16: 1001-1006
30. Plushner SL (2008) Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 42: 1660-1668
31. Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300: 281-290
32. Scheller J, Ohnesorge N, Rose-John S (2006) Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 63: 321-329
33. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H (2000) Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 151: 31-38
34. Siegall CB, Schwab G, Nordon RP, Fitzgerald DJ, Paston I (1990) Expression of the interleukin-6 receptor and interleukin-6 in prostate carcinoma cells. Cancer Res 50: 7786-7788
35. Sohara Y, Shimada H, Minkin C, Erdreich-Epstein A, Nolta JA, DeClerck YA (2005) Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res 65: 1129-1135
36. Taga T, Kinoshita T (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819
37. Takizawa H, Ohtoshi T, Ohta K, Yamashita N, Hirohata S, Hirai K, Hiramatsu K, Ito K (1993) Growth inhibition of human lung cancer cell lines by interleukin-6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res 53: 4175-4181
38. Wakuda R, Miki C, Kusunoki M (2001) Autoreactivity against interleukin 6 as a risk factor in elderly patients with colorectal carcinoma. Arch Surg 136: 1274-1279
39. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O (1990) Constitutive production of IL-6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 50: 6959-6965